[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Biotech company $VYNE is under scrutiny due to financial concerns and upcoming data. Investors are watching closely as phase 2b data for vitiligo treatment approaches.
$1933m is a market cap for a biotech company.
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1 Month: XXXXX +1,152%
1-Year High: XXXXXX on 2025-05-17
1-Year Low: X on 2025-05-26
Social Network | X |
---|---|
Engagements | XX |
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X +100%
1 Month: XX +140%
1-Year High: X on 2025-06-27
1-Year Low: X on 2025-05-01
Social Network | X |
---|---|
Mentions | X |
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $1933m in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1 Week: X +50%
1 Month: X +200%
1-Year High: X on 2025-05-24
1-Year Low: X on 2025-05-01
The most influential creators that mention $1933m in the last XX hours
Creator | Rank | Followers | Posts | Engagements |
---|---|---|---|---|
@streamtailvents | X | XX | X | XXX |
Sentiment 24-Hour Chart Data
Current Value: %
Daily Average: XX%
1-Year High: XX% on 2025-06-26
1-Year Low: XX% on 2025-06-26
Top assets mentioned In the posts about $1933m in the last XX hours
Top topics mentioned In the posts about $1933m in the last XX hours
market cap, $503m, $vyne, nft, signals, $nft, $44167m
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$VYNE Single-asset biotech since they stopped VYN202. Need capital raise after data. This P2b data will make or break the company"
@streamtailvents on X 2025-07-21 12:37:20 UTC XX followers, XXX engagements
"$VYNE looks interesting. Market cap $19.33m cash $50.3m negative EV with phase 2b VYN201 data coming near term for vitiligo. From P1b efficacy signal is convincing but hard to say whether can met the bar set by ruxolitinib (tho if lukewarm data could mitigate by safety profile since ruxo got black box label)"
@streamtailvents on X 2025-07-21 10:15:51 UTC XX followers, 1833 engagements